The relationship between CKD, cardiovascular disease, and diabetes is well documented.1-4 We know that CKD greatly amplifies the risks associated with hypertension, particularly in the diabetic patient. Therefore, the earlier these conditions are monitored the better for your patients....

Did you Know
  • Early CKD detection and treatment of anemia can help lower cardiovascular risks and progression to kidney failure
  • Timely identification and achievement of blood pressure goals may improve CKD outcomes2
Know the Facts
  • Over 26 million US adults have CKD and millions more are at risk3
  • CKD is the 9th leading cause of death in America1
  • The most common causes of CKD are hypertension and diabetes
  • Heart disease and infection are the leading causes of death in CKD patients
Risk Factors
  • High risk groups include patients with diabetes, hypertension, and family history of kidney disease
  • CKD is more prevalent among the elderly and African Americans, Hispanics, Pacific Islanders, and Native Americans4
Comorbidity Correlation
  • Diabetes and hypertension are the two leading risk factors for CKD
  • Obesity, specifically waist-to-hip (WHR) ratio, is associated with cardiac events in patients with CKD5
Multidisciplinary Approach
Help ensure successful prevention and control of CKD:
  • Screen patients for hypertension
  • Test and diagnose predisposing comorbidities
  • Treat all stages of CKD aggressively to guideline goals, including anemia
American Regent. Enriching the lives of anemia patients. ™

IMPORTANT SAFETY INFORMATION:

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Venofer® (iron sucrose injection, USP). Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. If hypersensitivity reactions or signs of intolerance occur during administration, stop Venofer® immediately. Monitor patients for signs and symptoms of hypersensitivity during and after Venofer® administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Venofer® when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

Venofer® may cause clinically significant hypotension. Monitor for signs and symptoms of hypotension following each administration of Venofer®. Hypotension following administration of Venofer® may be related to rate of administration and total dose delivered.

Venofer® is contraindicated in patients with known hypersensitivity to Venofer®. Do not administer to patients with evidence of iron overload.

In efficacy studies in non-dialysis dependent-CKD patients (N=139), the most frequent adverse events (≥5%) whether or not related to Venofer® administration, were nausea (8.6%), taste disturbance

(7.9%), peripheral edema (7.2%), diarrhea (7.2%), dizziness (6.5%), hypertension (6.5%), infusion site pain or burning (5.8%), dyspnea (5.8%), and vomiting (5.0%).

In multi-dose efficacy studies in HDD-CKD patients (N=231), the most frequent adverse events (> 5%) whether or not related to Venofer® administration, were hypotension (39.4%), muscle cramps (29.4%), nausea (14.7%), headache (12.6%), graft complications (9.5%), vomiting (9.1%), dizziness (6.5%) hypertension (6.5%), chest pain (6.1%), and diarrhea (5.2%). In the study of PDD-CKD patients (N=75), the most frequent adverse events, whether or not related to Venofer®, reported by ≥5% of these patients were infections and infestations (nasopharyngitis, sinusitis, upper respiratory tract, pharyngitis) (16.0%), diarrhea (8.0%), vomiting (8.0%), hypertension (8.0%), peripheral edema (5.3%), and nausea (5.3%).


Please see Full Prescribing Information.


References